Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Clinical Medication Journal》 2019-10
Add to Favorite Get Latest Update

Development of arginine vasopressin receptor antagonists in the treatment of hyponatremia

LIU Xin;ZHANG Xiao-yan;LI Yue-ling;ZHAO Zhi-gang;Department of Pharmacy,Beijing Tiantan Hospital,Capital Medical University;Department of Pharmacy,Guangzhou Red Cross Hospital;  
Arginine vasopressin(AVP) regulates body fluid and electrolyte balance.AVP secretion disorder can cause hyponatremia.At present,the AVP receptor include V_(1a),V_(1b),and V_2 subtypes.In terms of structure,vaptansin belongs to active non-peptide vasopressin receptor antagonists.Among them,the V_(1a) receptor antagonist(relcovaptan) has a preliminary effect in the treatment of Raynaud's disease and spasmolysis.SSR-149415 is a selective V_(1b) receptor antagonist,showing beneficial effects in the treatment of psychiatric disorders.V2 receptor antagnosits,including mozavaptan,lixivaptan,satavaptan,and tolvaptan,unlike diuretic action principle,it can improve hyponatremia and reduce hospital mortality congestive heart failure without affecting electrolyte excretion.Conivaptan,a non-selective V_(1a)/V_2 AVP receptor antagonist,is an FDA-approved intravenous infusion for the treatment of hyponatremia.This paper aims to provide a theoretical guidance for clinical treatment of hyponatremia by discussing the research progress of AVP receptor antagonists.
【CateGory Index】: R591.1
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved